William Blair analyst Matt Phipps has maintained their bullish stance on JSPR stock, giving a Buy rating today.
Matt Phipps has given his Buy rating due to a combination of factors that highlight Jasper Therapeutics’ strategic advancements and potential in the market. The company recently reported promising initial results from its Phase I/II BEACON study of the cKIT antibody briquilimab in treating chronic spontaneous urticaria. Despite some mixed dose response and safety data, the study demonstrated significant clinical efficacy, which positions the company well for future developments.
Jasper’s plans to initiate an adaptive Phase IIb study in the second half of 2025 further bolster its prospects. This approach allows for a seamless transition to Phase III development, potentially accelerating the timeline for bringing briquilimab to market. The anticipated clinical readout in late 2026 and subsequent Phase III initiation could position Jasper competitively, despite being slightly behind a key competitor. These strategic plans and the potential for strong clinical outcomes underpin Phipps’s positive outlook on Jasper’s stock.
In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $40.00 price target.